2,905 Shares in Cardinal Health, Inc. $CAH Purchased by Portfolio Design Labs LLC

Portfolio Design Labs LLC acquired a new position in Cardinal Health, Inc. (NYSE:CAH) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,905 shares of the company’s stock, valued at approximately $690,000.

Several other hedge funds have also recently modified their holdings of CAH. University of Texas Texas AM Investment Management Co. bought a new position in shares of Cardinal Health in the fourth quarter valued at approximately $26,000. Bank of Jackson Hole Trust bought a new stake in Cardinal Health during the fourth quarter worth $27,000. Jones Financial Companies Lllp boosted its position in Cardinal Health by 198.3% in the first quarter. Jones Financial Companies Lllp now owns 21,112 shares of the company’s stock worth $27,000 after purchasing an additional 14,034 shares during the last quarter. Palladiem LLC purchased a new position in shares of Cardinal Health in the 4th quarter worth about $28,000. Finally, Indiana Trust & Investment Management Co bought a new position in shares of Cardinal Health during the 1st quarter valued at approximately $29,000. Institutional investors own 87.17% of the company’s stock.

Insider Buying and Selling at Cardinal Health

In other Cardinal Health news, insider Michelle D. Greene sold 11,650 shares of Cardinal Health stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $235.72, for a total transaction of $2,746,138.00. Following the sale, the insider directly owned 10,330 shares of the company’s stock, valued at approximately $2,434,987.60. The trade was a 53.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jason M. Hollar sold 44,529 shares of Cardinal Health stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $236.18, for a total value of $10,516,859.22. Following the sale, the chief executive officer owned 190,603 shares in the company, valued at $45,016,616.54. This represents a 18.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 210,271 shares of company stock worth $49,626,657. Insiders own 0.12% of the company’s stock.

Cardinal Health Stock Performance

Shares of Cardinal Health stock opened at $228.95 on Friday. The company’s 50 day moving average price is $231.91 and its 200-day moving average price is $217.78. Cardinal Health, Inc. has a 52-week low of $145.87 and a 52-week high of $258.30. The stock has a market capitalization of $53.25 billion, a price-to-earnings ratio of 31.67, a P/E/G ratio of 1.26 and a beta of 0.49.

Cardinal Health (NYSE:CAH) last issued its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.42 by $0.49. The firm had revenue of $63.67 billion during the quarter, compared to the consensus estimate of $65.15 billion. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.08 earnings per share. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, equities research analysts forecast that Cardinal Health, Inc. will post 12.54 earnings per share for the current fiscal year.

Cardinal Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be given a $0.5158 dividend. This represents a $2.06 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, October 1st. Cardinal Health’s dividend payout ratio (DPR) is currently 28.49%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CAH. Citigroup increased their price target on Cardinal Health from $265.00 to $280.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. UBS Group upped their price target on shares of Cardinal Health from $274.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Wells Fargo & Company lifted their price objective on Cardinal Health from $245.00 to $277.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Robert W. Baird boosted their target price on Cardinal Health from $251.00 to $274.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings lowered Cardinal Health from a “buy (b+)” rating to a “buy (b)” rating in a research note on Wednesday. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Cardinal Health presently has an average rating of “Moderate Buy” and a consensus price target of $266.56.

Key Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage of Cardinal Health with a “moderate buy” or outperform-equivalent rating. RBC cited the integration of higher-margin services as a potential driver of future earnings outperformance. RBC Capital Starts Cardinal Health at Outperform
• Positive Sentiment: A Zacks analysis identified CAH as a potentially attractive long-term value stock, while recent coverage has highlighted Cardinal Health’s precision-medicine operations and higher-margin services as sources of sustained growth. Why Cardinal Health Is a Top Value Stock for the Long-Term
• Neutral Sentiment: Brokerages continue to assign Cardinal Health a consensus “moderate buy” rating. The constructive view is tempered by valuation and questions about the sustainability of recent earnings gains.
• Negative Sentiment: Multiple executives and insiders sold shares around $235–$237. Chief Executive Officer Jason Hollar sold a combined 124,529 shares worth approximately $29.4 million, while CEO Deborah Weitzman sold about $1.7 million. Other insider sales included Chief Accounting Officer Mary Scherer and executives Michelle Greene, Jessica Mayer, and Stephen Mason. The transactions substantially reduced several executives’ holdings and may signal that insiders are taking profits after the stock’s strong rally. Cardinal Health Insider Sale Filing
• Negative Sentiment: Although Cardinal Health reported adjusted quarterly EPS of $2.91, well above the $2.42 consensus, an analysis noted that a significant portion of the earnings improvement came from a one-time tariff refund. That raises concerns about the durability of the earnings beat and may be contributing to the weaker stock performance. Cardinal Health Earnings Analysis

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.